Azacitidine
Adverse Event
Sun Yat-sen UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Adverse Event cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Lei Li | Phase 3 | B |
Acalabrutinib Polish Lymphoma Research Group | Phase 2 | B |
Solu-Cortef Mahidol University | Phase 2 | CCC |
Eloxatin Sun Yat-sen University | N/A | D |
Tucidinostat Sun Yat-sen University | N/A | D |
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →